NASDAQ:CARM Carisma Therapeutics (CARM) Stock Price, News & Analysis → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free CARM Stock Alerts $1.63 0.00 (0.00%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$1.60▼$1.6750-Day Range$1.63▼$2.6052-Week Range$1.53▼$9.77Volume97,631 shsAverage Volume154,761 shsMarket Capitalization$67.72 millionP/E RatioN/ADividend YieldN/APrice Target$8.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Carisma Therapeutics alerts: Email Address Carisma Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside439.9% Upside$8.80 Price TargetShort InterestBearish8.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.65) to ($1.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.73 out of 5 starsMedical Sector652nd out of 927 stocksPharmaceutical Preparations Industry288th out of 420 stocks 3.5 Analyst's Opinion Consensus RatingCarisma Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCarisma Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.53% of the float of Carisma Therapeutics has been sold short.Short Interest Ratio / Days to CoverCarisma Therapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Carisma Therapeutics has recently increased by 4.43%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCarisma Therapeutics does not currently pay a dividend.Dividend GrowthCarisma Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CARM. Previous Next 3.5 News and Social Media Coverage News SentimentCarisma Therapeutics has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Carisma Therapeutics this week, compared to 1 article on an average week.Search Interest1 people have searched for CARM on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Carisma Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Carisma Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.00% of the stock of Carisma Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.27% of the stock of Carisma Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Carisma Therapeutics are expected to grow in the coming year, from ($1.65) to ($1.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Carisma Therapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Carisma Therapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCarisma Therapeutics has a P/B Ratio of 2.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Carisma Therapeutics Stock (NASDAQ:CARM)Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.Read More CARM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CARM Stock News HeadlinesApril 24, 2024 | finance.yahoo.comCarisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingApril 22, 2024 | prnewswire.comCarisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual MeetingMay 1, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.April 12, 2024 | markets.businessinsider.comBuy Rating Affirmed: Promising Clinical Data and Strategic Shift Bolster Carisma Therapeutics’ OutlookApril 12, 2024 | markets.businessinsider.comPromising Future for Carisma Therapeutics’ Cancer Immunotherapy: A Buy Rating AnalysisApril 11, 2024 | markets.businessinsider.comBuy Rating Affirmed on Carisma Therapeutics Amid Promising Early Research and Pipeline PotentialApril 8, 2024 | msn.comCarisma Therapeutics Welcomes New Board Member John Hohneker Amid Company EvolutionApril 4, 2024 | seekingalpha.comWall Street Breakfast Podcast: Perma-Fix Advances In PFAS Chemical EliminationMay 1, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.April 3, 2024 | finance.yahoo.comCarisma Therapeutics to Present at Upcoming ConferencesApril 1, 2024 | bizjournals.comPenn spinout Carisma Therapeutics reducing workforce by 37%April 1, 2024 | finance.yahoo.comCarisma Therapeutics Announces Changes to its Board of DirectorsApril 1, 2024 | finance.yahoo.comCarisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 26, 2024 | msn.comCarisma Therapeutics to Highlight Breakthroughs in Cancer Immunotherapy at AACR Annual MeetingMarch 21, 2024 | finance.yahoo.comCarisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual MeetingMarch 6, 2024 | msn.comCarisma Therapeutics' CEO to Share Insights at TD Cowen Health Care ConferenceFebruary 28, 2024 | finance.yahoo.comCarisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care ConferenceFebruary 28, 2024 | prnewswire.comCarisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care ConferenceFebruary 27, 2024 | finance.yahoo.comIndividual investors account for 30% of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) ownership, while institutions account for 23%January 7, 2024 | seekingalpha.comCarisma Therapeutics: New Frontiers In Cell Therapy, But Too Early To Buy InDecember 21, 2023 | finance.yahoo.comCarisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 15, 2023 | markets.businessinsider.comInnovative CAR-M Therapy Advancements Fuel Buy Rating for Carisma TherapeuticsDecember 9, 2023 | finance.yahoo.comHere's Why We're A Bit Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn SituationDecember 1, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Lantheus (LNTH) and Carisma Therapeutics (CARM)November 28, 2023 | markets.businessinsider.comCarisma Therapeutics Gets FDA Clearance To Start Phase 1 Study Of CT-0525 In Solid TumorsNovember 28, 2023 | markets.businessinsider.comCarisma Therapeutics Announces FDA Clearance Of IND For CT-0525 - Quick FactsNovember 28, 2023 | finance.yahoo.comCarisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-MonocyteSee More Headlines Receive CARM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today5/01/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CARM CUSIPN/A CIK1485003 WebN/A Phone617-444-8550Fax617-858-0911Employees107Year FoundedN/APrice Target and Rating Average Stock Price Target$8.80 High Stock Price Target$12.00 Low Stock Price Target$6.00 Potential Upside/Downside+439.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,880,000.00 Net Margins-582.34% Pretax Margin-582.34% Return on Equity-154.04% Return on Assets-71.58% Debt Debt-to-Equity Ratio0.01 Current Ratio5.06 Quick Ratio5.06 Sales & Book Value Annual Sales$14.92 million Price / Sales4.54 Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book2.47Miscellaneous Outstanding Shares41,543,000Free Float34,481,000Market Cap$67.72 million OptionableNo Data Beta0.95 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Steven Kelly (Age 59)President, CEO & Director Comp: $666kMr. Michael Klichinsky Ph.D. (Age 34)Pharm.D., PharmD, Co-Founder & Chief Scientific Officer Comp: $469kMr. Richard S. Morris CPA (Age 50)CFO, Chief Compliance Officer, Treasurer, Prin. Financial Off. & Prin. Acc. Off. Comp: $570kMr. Saar Gill M.D.Ph.D., Co-FounderDr. Daniel J. Cushing FCPPh.D., Chief Technology & Development OfficerMr. Eric H. Siegel J.D. (Age 59)MBA, General Counsel & Corporate Secretary Ms. Terry ShieldsSenior Vice President of Human ResourcesMr. Tom Wilton (Age 50)Chief Business Officer More ExecutivesKey CompetitorsYS BiopharmaNASDAQ:YSAssembly BiosciencesNASDAQ:ASMBViveon Health AcquisitionNYSE:VHAQLandos BiopharmaNASDAQ:LABPSELLAS Life Sciences GroupNASDAQ:SLSView All CompetitorsInstitutional OwnershipTrustees of The University of PennsylvaniaSold 507,737 shares on 2/14/2024Ownership: 3.102%View All Institutional Transactions CARM Stock Analysis - Frequently Asked Questions Should I buy or sell Carisma Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Carisma Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CARM shares. View CARM analyst ratings or view top-rated stocks. What is Carisma Therapeutics' stock price target for 2024? 5 analysts have issued 12-month target prices for Carisma Therapeutics' shares. Their CARM share price targets range from $6.00 to $12.00. On average, they predict the company's stock price to reach $8.80 in the next twelve months. This suggests a possible upside of 439.9% from the stock's current price. View analysts price targets for CARM or view top-rated stocks among Wall Street analysts. How have CARM shares performed in 2024? Carisma Therapeutics' stock was trading at $2.93 at the beginning of the year. Since then, CARM shares have decreased by 44.4% and is now trading at $1.63. View the best growth stocks for 2024 here. When is Carisma Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CARM earnings forecast. How were Carisma Therapeutics' earnings last quarter? Carisma Therapeutics, Inc. (NASDAQ:CARM) posted its earnings results on Monday, April, 1st. The company reported ($0.52) EPS for the quarter. The business earned $4.29 million during the quarter, compared to the consensus estimate of $4 million. Carisma Therapeutics had a negative net margin of 582.34% and a negative trailing twelve-month return on equity of 154.04%. Who are Carisma Therapeutics' major shareholders? Carisma Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Carisma Therapeutics? Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CARM) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority Gold😱 This phenomenon is smashing regular market gainsMillPubElon’s New Device is About to Shock the WorldInvestorPlaceYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingA once-in-a-century investment opportunityStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
